Obsidian Therapeutics is a biotechnology company developing next-generation cell and gene therapies with pharmacologic operating systems. Based upon founding work on destabilizing domains by Professor Thomas Wandless, a leading researcher in chemical and systems biology, Obsidian's lead programs are CAR-T products that incorporate controllable functions for enhanced safety and efficacy. Obsidian was founded in 2015 by Atlas Venture and is funded by a strong syndicate of venture investors.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
12/06/17 | $49,500,000 | Series A |
Alexandria Real Estate Equities Amgen Business Development Atlas Venture ShangPharma Investment Group Takeda Ventures Vertex Ventures | undisclosed |